Table I.
Observed and expected newly diagnosed skin cancers during 2020 in a skin cancer referral center in Northern Greece
| Variables | Expected | Observed | P value∗ |
|---|---|---|---|
| All skin cancers | 855 | 598 | <.001 |
| Melanomas | 165 | 105 | <.001 |
| Breslow thickness (mm) | |||
| Mean | 1.8 ± 2.0 | 2.2 ± 1.9 | .1838† |
| Median | 1.5 | 1.8 | |
| Melanoma stage | |||
| 0 | 44 (26.7%) | 19 (18.1%) | <.001 |
| IA | 23 (13.9%) | 11 (10.5%) | |
| IB | 29 (17.6%) | 19 (18.1%) | |
| IIA | 12 (7.3%) | 9 (8.6%) | |
| IIB | 11 (6.7%) | 8 (7.6%) | |
| IIC | 6 (3.6%) | 8 (7.6%) | |
| III | 19 (11.5%) | 15 (14.3%) | |
| IV | 21 (12.7%) | 16 (15.2%) | |
| Age (years) | 58.69 ± 15.05 | 51.12 ± 11.36 | <.001† |
| Male:female | 1.1:1 | 1:1 | |
| Previous melanoma history | 12 (7.2%) | 13 (12.4%) | |
| Basal cell carcinomas | 498 | 387 | <.001 |
| Age (years) | 72.6 ± 19.4 | 67.8 ± 14.66 | <.001† |
| Male:female | 1.6:1 | 1.2:1 | |
| Squamous cell carcinomas | 192 | 106 | <.001 |
| Age (years) | 75.2 ± 9.3 | 73.4 ± 12.11 | .267† |
| Male:female | 2.9:1 | 2.8:1 |
Bold means statistically significant.
∗
Pearson's χ2 test.
†
Student t test.